Skip to content
value.today
Emmaus Life Sciences, Inc. logo

Emmaus Life Sciences, Inc.

EMMA
$12 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$12 M
For year ending December-2025
Net income
$-7 M
-60.2% margin
SEC filing
Employees
33
As of December 31, 2025
SEC filing

Emmaus Life Sciences, Inc. in brief

Emmaus Life Sciences, Inc. is a listed company in the Biotechnology industry, based in Torrance, California, USA. Its last known market value was $12 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $12 M and a net loss of $7 M. It employs about 33 people. Its largest product and service lines by sales in 2025 were Endari - US (73%) and Endari - International (26%).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Emmaus Life Sciences, Inc.

We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases. Our only product, Endari® (prescription grade L-glutamine oral powder) is approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari® was approved for marketing in the United Arab Emirates, or U.A.E, Qatar, Kuwait, Bahrain and Oman. Our application for marketing authorization in the Kingdom of Saudi Arabia, or KSA, is pending. While the application is pending, the FDA approval of Endari® can be referenced to allow access to Endari® in Saudi Arabia on a named-patient basis. In January 2025, Endari® was afforded market exclusivity in the KSA by the KSA’s unified purchasing system which extends to all KSA government institutions, including hospitals under the Ministry of Health, Military Hospitals, the National Guard, the Security Forces, and King Faisal Specialty Hospitals and Research Centers.

From the company's annual report filed with the US SEC: read the report

Emmaus Life Sciences, Inc. timeline

7 events, 1999–2023
  1. 1999
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2004
  4. ✎
    Renamed SalesTactix, Inc.
    Formerly Age Research Inc.
  5. 2005
  6. ✎
    Renamed Strativation, Inc.
    Formerly SalesTactix, Inc..
  7. 2007
  8. ✎
    Renamed Cns Response, Inc.
    Formerly Strativation, Inc..
  9. 2015
  10. ✎
    Renamed MYnd Analytics, Inc.
    Formerly Cns Response, Inc..
  11. 2019
  12. ✎
    Renamed Emmaus Life Sciences, Inc.
    Formerly MYnd Analytics, Inc..
  13. 2023
  14. 💰
    Record revenue of $30 million
    FY2023, the highest of the 8 years on record.

Events of Emmaus Life Sciences, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$26 M$52 M$79 M$105 M2020202120222023

World rank over time

▼ down 12,027 places since 2020
2020-01-01: #19014#19,01420202021-01-01: #20057#20,05720212022-01-07: #24958#24,95820222022-12-25: #24958#24,95820222023-07-30: #31041#31,0412023

Rank in USA: #3,717 (Jan 2020) · #3,973 (Jan 2021) · #4,647 (Jan 2022) · #5,354 (Dec 2022) · #5,363 (Jul 2023)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-38.8%
Operating margin
1.8%
Return on equity
—
Liabilities / assets
396.6%
Net debt
$25M
Revenue growth
-25.2%
R&D / revenue
2.5%
Revenue per employee
$377 K
Profit per employee
$-227 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $16M, net income $-73M$16MFY18Fiscal year ending Dec 2019: revenue $23M, net income $-55M$23MFY19Fiscal year ending Dec 2020: revenue $23M, net income $1M$23MFY20Fiscal year ending Dec 2021: revenue $21M, net income $-16M$21MFY21Fiscal year ending Dec 2022: revenue $18M, net income $-11M$18MFY22Fiscal year ending Dec 2023: revenue $30M, net income $-4M$30MFY23Fiscal year ending Dec 2024: revenue $17M, net income $-6M$17MFY24Fiscal year ending Dec 2025: revenue $12M, net income $-7M$12MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$12M-25.2%$0M$-7M-60.2%
Dec 2024$17M-43.8%$-2M$-6M-38.7%
Dec 2023$30M+61.0%$4M$-4M-12.6%
Dec 2022$18M-10.8%$-7M$-11M-57.7%
Dec 2021$21M-11.0%$-6M$-16M-77.4%
Dec 2020$23M+1.8%$-0M$1M5.8%
Dec 2019$23M+38.2%$-5M$-55M-241.1%
Dec 2018$16M—$-8M$-73M-441.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-0M$0M$-0M$-0.12—
Dec 2024$-2M$0M$-2M$-0.10—
Dec 2023$-2M$0M$-2M$-0.07—
Dec 2022$-5M$0M$-5M$-0.21—
Dec 2021$-1M$0M$-1M$-0.32—
Dec 2020$-2M$0M$-2M$30.00—
Dec 2019$-5M$0M$-5M$-1.30—
Dec 2018$-6M$0M$-6M$-1.97—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$16M
Net income, trailing 12 months
$-6M
RevenueNet income
Three months to Sep 2024: revenue $5M, net income $2M$5MSep ’24Three months to Dec 2024 (from the annual report): revenue $3M, net income $-2M$3MDec ’24Three months to Mar 2025: revenue $2M, net income $-2M$2MMar ’25Three months to Jun 2025: revenue $3M, net income $-1M$3MJun ’25Three months to Sep 2025: revenue $3M, net income $-2M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $4M, net income $-2M$4MDec ’25Three months to Mar 2026: revenue $2M, net income $-3M$2MMar ’26Three months to Jun 2026: revenue $6M, net income $1M$6MJun ’26

Latest quarter to Jun 2026: revenue $6M (+124.1% on a year earlier), net income $1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Emmaus Life Sciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$12 M
Operating income
$0 M
Net income
$-7 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$21 M
Total liabilities
$85 M
Total equity
$-64 M

As of December-2025

Insider trading at Emmaus Life Sciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$15 K
4 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$15 K
open market only
Insiders on file
23
since
$15 K-$2 K$0Nov 2023: bought $2 K (4 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $2 K (2 trades)DecFeb 2024: bought $15 K (4 trades), sold $0 (0 trades)FebSep 2024: bought $800 (1 trades), sold $0 (0 trades)SepMay 2025: bought $1 K (1 trades), sold $0 (0 trades)MayAug 2025: bought $2 K (1 trades), sold $0 (0 trades)AugAug 2026: bought $15 K (4 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Emmaus Life Sciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Willis C. LeeCEO, DirectorBuyindirect+100,000$0.050$5 K690,167Form 4
filed Willis C. LeeCEO, DirectorBuyindirect+94,767$0.060$6 K590,167Form 4
filed Willis C. LeeCEO, DirectorBuyindirect+50,000$0.050$3 K495,400Form 4
filed Willis C. LeeCEO, DirectorBuyindirect+46,000$0.040$2 K445,400Form 4
filed Willis C. LeeCEO, DirectorBuyindirect+170,000$0.010$2 K275,400Form 4
filed Willis C. LeeCEO, DirectorBuyindirect+70,000$0.020$1 K229,400Form 4
filed Seah H. LimDirectorBuy+20,000$0.040$8004.61 MForm 4
filed Willis C. LeeCo-President & COO, DirectorBuyindirect+77,000$0.130$10 K159,400Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Emmaus Life Sciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 1-for-10 reverse split

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Emmaus Life Sciences, Inc. scorecard#

Passes 3 of the 15 checks that could be worked out: strongest in profitability (2 of 4), weakest in growth (0 of 6). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-25.2%Revenue down 25.2% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-12.2%-12.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-12.2%-12.2% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.12 vs -0.10Diluted EPS -0.12 in fiscal 2025 against -0.10 the year before (report's currency).
    • ✗Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against $1 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability2 of 4
    • ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median1.9%1.9% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier1.9%1.9% in fiscal 2025 against -35.8% in 2022.
  • Financial health0 of 4
    • ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.11 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✗Net debt below three years of EBITDA92.6×Net debt 92.6 times EBITDA in fiscal 2025.
    • ✗Operating income covers interest five times0.0×Operating income 0.0 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Emmaus Life Sciences, Inc.'s statements, beside the median of Biotechnology.

Emmaus Life Sciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin1.9%-60.5%
Net margin-60.2%-68.9%
Revenue growth, 3 years a year-12.2%12.9%
Revenue growth-25.2%15.8%
Free cash flow margin-0.1%-61.5%

3of 9on the Piotroski tests of financial strength

  • Revenue fell 25.2% against the year before.
  • Net loss of $7 million, the 5th loss-making year in a row.
  • Free cash flow was negative: -$0 million.
  • Shareholders' equity is negative: -$64 million.

Emmaus Life Sciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Emmaus Life Sciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Revenue121730182123231.30.10.1
Cost of revenue0.91.21.32.63.32.21.10.80.10.0
Gross profit121528161721220.50.1—
Research and development0.30.71.21.74.12.42.2———
Selling and marketing2.96.08.67.55.94.97.01.61.20.5
General and administrative8.21115131314177.74.62.5
Operating expenses11172522232126117.2r3.9
Operating income0.2−1.93.5−6.6−6.1−0.0−4.5−10−7.1−3.8
Interest expense and finance costs7.15.57.45.03.16.028———
Share of profit of associates——−1.7−1.9−2.7−2.1r−0.4———
Other non-operating income (expense)———————−0.1−0.0−2.2
Income before tax−7.5−6.4−3.8−11−161.0r−55−10−7.1−5.9
Income tax0.00.0−0.10.10.0−0.40.20.00.00.0
Net income including minority interests−7.5−6.5−3.7−11−161.4r−55−10−7.1—
Minority interests' share of net income———————0.70—
Net income attributable to shareholders−7.5−6.5−3.7−11−161.4r−55−9.6−7.1−5.9
Earnings per share, basic-0.12-0.10-0.07-0.21-0.32r30.00r-1.30-1.86-2.52-9.26
Earnings per share, diluted-0.12-0.10-0.07-0.21-0.32r30.00r-1.30-1.86-2.52-9.26
Shares, weighted average (basic)64635349494942———
Shares, weighted average (diluted)6463534949——5.22.80.6
Balance sheet
Cash and cash equivalents2.11.42.52.02.32.51.83.35.40.3
Short-term investments——————28———
Receivables2.82.65.5r0.41.00.22.20.10.00.0
Inventory1.61.61.72.44.47.18.0———
Other current assets0.40.20.60.40.40.6r0.70.10.00.0
Current assets7.76.8126.39.111413.55.70.4r
Property, plant and equipment0.10.00.10.10.10.10.20.10.10.0
Right-of-use (leased) assets0.81.52.32.83.54.14.5———
Goodwill———————1.4——
Other intangible assets———————0.10.10.1
Investments in associates———19181613———
Long-term investments————————0.2—
Total assets212435485760r595.26.10.5r
Accounts payable6.05.25.1r3.82.7r2.07.30.30.70.4
Current liabilities696462543723331.21.51.5
Long-term debt———————0.6——
Lease liabilities (non-current)1.40.81.82.63.33.53.9———
Non-current liabilities——————380.70.00.0
Total liabilities858083827865711.91.51.6
Retained earnings−270−263−256−252−241−225r−226−85−76−69
Shareholders' equity−64−56−48−34−21−5.2r−114.04.5−1.1r
Minority interests———————−0.7——
Total equity———————−12r4.5—
Total liabilities and equity212435485760r595.26.10.5r
Shares outstanding706462504949r487.44.31.9
Cash-flow statement
Depreciation and amortization0.00.00.00.10.10.10.10.10.00.0
Share-based compensation0.00.31.30.00.60.7—1.62.10.8r
Cash from operating activities−0.0−2.3−1.5−5.1−1.3−2.5−4.5−9.0−4.8−3.0
Capital expenditure−0.0−0.0−0.0−0.0−0.1−0.0−0.1−0.1−0.1−0.0
Intangible assets bought————————−0.0−0.1
Acquisitions, net of cash acquired———————−0.3——
Cash from investing activities2.22.5−0.4−2.4−6.45.5−1.5−0.4−0.5−0.1
Debt repaid———————−0.0——
Shares issued—————0.18.60.93.0—
Cash from financing activities−1.4−1.42.57.27.4−2.33.97.2102.9
Change in cash0.7−1.20.5−0.3−0.20.7−2.1−2.25.1−0.1
Report10-K10-K10-K10-K10-K10-K10-K/A10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Emmaus Life Sciences, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Endari - US$9 M73%
  • Endari - International$3 M26%
  • Other$0 M1.8%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Emmaus Life Sciences, Inc. operates: 5 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 7 subsidiaries on file.

Emmaus Life Sciences, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—
🇰🇷 South Korea2 subsidiaries—
🇮🇪 Ireland1 subsidiary—
🇯🇵 Japan1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Emmaus Life Sciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling
  • Auditor changedFiling

Auditor changed 3 · Directors and officers 9 · Material agreement 5 · New debt 2 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Results announced 11

Emmaus Life Sciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Material agreementNew debtUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Auditor changed8-K
Directors and officers8-K
Auditor changedResults announced8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreementNew debtUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Emmaus Life Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2020$4 MPrivate placement after listing$2 to $10 million18optionsSEC
Jan 2011$3 MNo. 4$2 to $10 million12optionsSEC
Oct 2010$2 MNo. 3Under $2 million4equity, debt, optionsSEC
Aug 2009$2 MNo. 2$2 to $10 million6equity, optionsSEC
Jun 2009$1 MNo. 1Under $2 million1optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Emmaus Life Sciences, Inc. compares in Biotechnology

  • Revenue$12 M · higher than 46% of 647
  • Net margin-38.8% · higher than 54% of 408
  • Revenue growth-25.2% · higher than 28% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Emmaus Life Sciences, Inc.🇺🇸$12 M—-38.8%-25.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Emmaus Life Sciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Emmaus Life Sciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Emmaus Life Sciences, Inc.? Suggest a correction